-+ 0.00%
-+ 0.00%
-+ 0.00%

Evotec, Bristol Myers Squibb Secure Second US FDA Approval for Drug Candidate

MT Newswires·11/19/2026 02:15:51
Listen to the news
02:15 AM EST, 11/19/2026 (MT Newswires) -- German life science company Evotec (EVT.F) and Bristol Myers Squibb obtained a second investigational new drug clearance from the US Food and Drug Administration under their strategic protein degradation partnership. The newly cleared drug candidate, a cereblon E3 ligase modulator, is expected to enter a phase 1 clinical trial in 2027, according to a Thursday release. The companies' first candidate under the partnership began phase 1 trials for advanced clear cell renal cell carcinoma in March.